WallStSmart

NVIDIA Corporation (NVDA)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

NVIDIA Corporation generates 10615% more annual revenue ($215.94B vs $2.02B). VISN leads profitability with a 347.7% profit margin vs 55.6%. NVDA appears more attractively valued with a PEG of 0.76. NVDA earns a higher WallStSmart Score of 79/100 (B+).

NVDA

Strong Buy

79

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.7Quality: 8.5
Piotroski: 3/9Altman Z: 6.75

VISN

Strong Buy

66

out of 100

Grade: B-

Growth: 4.7Profit: 6.5Value: 4.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NVDA.

VISNSignificantly Overvalued (-41.1%)

Margin of Safety

-41.1%

Fair Value

$13.59

Current Price

$11.93

$1.66 premium

UndervaluedFair: $13.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVDA6 strengths · Avg: 10.0/10
Market CapQuality
$5.09T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.5%10/10

Every $100 of equity generates 102 in profit

Profit MarginProfitability
55.6%10/10

Keeps 56 of every $100 in revenue as profit

Operating MarginProfitability
65.0%10/10

Strong operational efficiency at 65.0%

Revenue GrowthGrowth
73.2%10/10

Revenue surging 73.2% year-over-year

EPS GrowthGrowth
95.6%10/10

Earnings expanding 95.6% YoY

VISN4 strengths · Avg: 9.5/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
347.7%10/10

Keeps 348 of every $100 in revenue as profit

EPS GrowthGrowth
704.0%10/10

Earnings expanding 704.0% YoY

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Areas to Watch

NVDA3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
42.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
30.7x2/10

Trading at 30.7x book value

VISN2 concerns · Avg: 2.0/10
PEG RatioValuation
2.942/10

Expensive relative to growth rate

Revenue GrowthGrowth
-57.6%2/10

Revenue declined 57.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVDA

The strongest argument for NVDA centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 55.6% and operating margin at 65.0%. Revenue growth of 73.2% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 347.7% and operating margin at 7.5%.

Bear Case : NVDA

The primary concerns for NVDA are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 42.7x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

NVDA profiles as a growth stock while VISN is a declining play — different risk/reward profiles.

VISN carries more volatility with a beta of 2.38 — expect wider price swings.

NVDA is growing revenue faster at 73.2% — sustainability is the question.

NVDA generates stronger free cash flow (34.9B), providing more financial flexibility.

Bottom Line

NVDA scores higher overall (79/100 vs 66/100), backed by strong 55.6% margins and 73.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

NVIDIA Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

Nvidia Corporation is an American multinational technology company incorporated in Delaware and based in Santa Clara, California. It designs graphics processing units (GPUs) for the gaming and professional markets, as well as system on a chip units (SoCs) for the mobile computing and automotive market.

Visit Website →

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?